The contributions of medical research to understanding health and treating disease are a modern miracle.
If our nation hadn’t spent the last decade cutting funding for medical research, might we have an Ebola vaccine by now? Or made breakthroughs in the treatment of cancer, developed new approaches to treating heart disease, or made progress against antibiotic-resistant infections?
The possibilities are endless. Unfortunately, we will never know what might have been possible.
When patients and visitors come to U-M’s medical campus, they often hear the sound of music provided by the Gifts of Art program – whether it’s a harp playing in the waiting area near the operating rooms, a guitarist visiting the room of a hospitalized child, or a jazz band playing a free lunchtime concert on a Thursday in the main lobby of University Hospital.
But on Sunday nights, some of U-M’s doctors, nurses, scientists, dentists and students gather to make music of their own — in the Life Sciences Orchestra. For the last 14 years, the LSO has given these health and science professionals an outlet for their own musical talents — and let them meet people from across the vast U-M life science community.
The three-year strategic collaboration will bring scientists from one of the nation’s top medical research institutions together with scientists from one of the world’s leading developers of biologic therapies.
“We are thrilled to partner with MedImmune in a collaborative and creative way to bring new innovations to market,” says Steven Kunkel, Ph.D., senior associate dean for research at the U-M Medical School and Endowed Professor of Pathology Research. “This strategic partnership, one of the first of its kind for our institution, speaks to our desire to collaborate with industry to accelerate translation of U-M’s cutting-edge research to impact patients.”
The partnership will initially focus on oncology, leveraging the strength of the U-M Comprehensive Cancer Center. U-M cancer scientists, led by center director Max Wicha, M.D., have won more research grant dollars from the National Cancer Institute than researchers at any other academic medical center.
“Working with MedImmune to explore new ways to target treatments is a natural progression of the basic scientific discoveries that our teams have made in the last decade,” says Wicha, who is also the Distinguished Professor of Oncology in the Department of Internal Medicine at the U-M Medical School.
UMMS and MedImmune scientists will cooperate on studies that aim to translate scientific discoveries from the laboratory into new candidates for treating cancer as well as heart disease, digestive disease, lung disease and diseases caused by inflammation. Continue reading →
NOTICE: Except where otherwise noted, all articles are published under a Creative Commons Attribution 3.0 license. You are free to copy, distribute, adapt, transmit, or make commercial use of this work as long as you attribute the University of Michigan Health System as the original creator and include a link to this article.